Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade

Reference:
1 review Write a review
Size

,

Brand

Product type

Clonality

Expression system

Applications

,

Product nameBamlanivimab Biosimilar - Anti-Covid Spike RBD mAb - Research Grade
SpeciesHumanized
Expression systemMammalian
Molecular weight150kDa
Purity>85%
BufferPBS pH7.5
Delivery conditionBlue ice (+4°)
Delivery lead time in business days3-5 days if in stock; 3-5 weeks if production needed
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage condition4°C for short term; -20°C for long term
BrandProteoGenix
ApplicationsELISA,WB
Aliases /SynonymsBamlanivimab,Bamlanivimab,Covid Spike RBD,anti-Covid Spike RBD
ReferencePX-TA1031
NoteFor research use only. Not suitable for human use.
IsotypeIgG1
ClonalityMonoclonal Antibody

Description of Bamlanivimab Biosimilar - Anti-Covid Spike RBD mAb - Research Grade

General information on Anti-SARS-CoV2 Spike RBD (Bamlanivimab) Monoclonal Antibody

Bamlanivimab is a synthetic monoclonal antibody (mAb) that was developped from the first blood samples from COVID-19 recovered patients in the United States. Bamlanivimab is a neutralizing IgG1 mAb targetting the SARS-CoV-2 spike, which prevents the virus from entering human cells. It has been found to recognize first type and variants referenced as PX-COV-P046 and PX-COV-P052.

SDS-PAGE for Bamlanivimab Biosimilar - Anti-Covid Spike RBD mAb

Bamlanivimab Biosimilar - Anti-Covid Spike RBD mAb, on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

Publication

  • Efficient Neutralization of SARS-CoV-2 Omicron and Other VOCs by a Broad Spectrum Antibody 8G3,Hang Ma, Chien-Te K. Tseng, Huifang Zong, Yunji Liao, et al., bioRxiv 2022.02.25.482049; doi: https://doi.org/10.1101/2022.02.25.482049
  • Evelien Vanderlinden, Arnaud Boonen, Sam Noppen, Geert Schoofs, Maya Imbrechts, Nick Geukens, Robert Snoeck, Annelies Stevaert, Lieve Naesens, Graciela Andrei, Dominique Schols, PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding, Antiviral Research, Volume 217, 2023, 105700, ISSN 0166-3542, https://doi.org/10.1016/j.antiviral.2023.105700.

Reviews

  • Toshi

    This antibody along with other therapeutic antibodies were tested in surrogate virus neutralization test using spike trimers and ACE2 protein. This antibody showed expected neutralization of wild type, Alpha, Gamma, and Delta variants (IC50 135.73 ng/mL for the wild type, 185.54 ng/mL for Alpha, >500 ng/mL for Gamma and Delta).

REVIEW YOUR PRODUCT

Add a review

Your email address will not be published. Required fields are marked *

Related products

RBD Domain
Antigen

RBD Domain

PX-COV-P046 297.5$
Human IgG1 LALA Isotype Control antibody (HyHEL-10)
Isotype Control

Human IgG1 LALA Isotype Control antibody (HyHEL-10)

PTX17885 189$
Stable Isotope Labelled Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
SIL

Stable Isotope Labelled Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade

PX-TA1031-SIL 15750$

Contact us

Send us a message from the form below







    Cart (0 Items)

    Your cart is currently empty.

    View Products